Advertisement

Diagnostics company Quanterix Corp. today announced an evaluation agreement with Novartis Diagnostics under which the unit of Novartis AG will look at the potential use of Quanterix’s technology on a neuron-specific protein target.

Cambridge-based Quanterix offers a Single Molecule Array (SiMoA) technology for in vitro and life sciences research markets. The company claims that the digital nature of SiMoA offers a 1,000-fold improvement in sensitivity compared with analog-only technology.

SOURCE

Advertisement
Advertisement